SEC Company Response from Addex Therapeutics Ltd. (ADXN) (CIK 0001574232) (ADXN) — May 12, 2023

Addex Therapeutics Ltd. (ADXN) (CIK 0001574232)
Date: May 12, 2023 · CIK: 0001574232 · Accession: 0001104659-23-059720

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-271611

Date

May 12, 2023

Author

Tim Dyer

Form

CORRESP

Company

Addex Therapeutics Ltd. (ADXN) (CIK 0001574232)

Letter

United States Securities and Exchange Commission Division of Corporation Finance RE: Addex Therapeutics Ltd Withdrawal of Acceleration Request Registration Statement on Form F-1 File No. 333-271611

Dear Mr. Campbell:

Reference is made to our letter, filed as correspondence via EDGAR on May 11, 2023, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for Friday, May 12, 2023, at 4:00 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time, and we hereby formally withdraw our request for acceleration of the effective date.

Very truly yours,
Addex Therapeutics Ltd.

Show Raw Text

CORRESP
1
filename1.htm

Addex Therapeutics
Ltd

Chemin des Mines 9,

CH-1202 Geneva, Switzerland

    May 12, 2023
    Via Edgar

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3561

Attn: Alan Campbell

 RE: Addex Therapeutics Ltd

Withdrawal
of Acceleration Request

Registration Statement on Form F-1

File No. 333-271611

Dear Mr. Campbell:

Reference is made to our letter, filed as correspondence
via EDGAR on May 11, 2023, in which we requested the acceleration of the effective date of the above-referenced Registration Statement
for Friday, May 12, 2023, at 4:00 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are
no longer requesting that such Registration Statement be declared effective at this time, and we hereby formally withdraw our request
for acceleration of the effective date.

    Very truly yours,

    Addex Therapeutics Ltd.

    /s/ Tim Dyer

    Tim Dyer

    Chief Executive Officer

 cc: Josh Kaufman, Cooley LLP

Marc Recht, Cooley
LLP

David C. Boles, Cooley (UK) LLP

Frank Gerhard, Homburger AG

SecProbe.io